Vaccine Adjuvants Market: Industry to reach USD 1.2 billion by 2028

"The vaccine adjuvants market is projected to grow at a CAGR of 6.9% during the forecast period of 2023-2028."

The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.

Download Free Sample PDF @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=597366

"The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market"

Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.

"infectious disease segment accounted for the largest share of the disease type segment in 2022."

Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.



"Asia Pacific region is likely to grow at a faster pace."

The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 80%, and Demand Side - 20%
By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

Dynavax Technologies (US)
Croda International plc (UK)
GSK plc (UK)
Seppic (France)
Novavax (US)
SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
Agenus Inc. (US)
Phibro Animal Health Corporation (US)
Aurorium (Vertellus) (US)
Merck KGaA (Germany)
Vaxine Pty Ltd. (Australia)
Hawaii Biotech Inc. (US)
CSL Limited (Australia)
OZ Biosciences (US)
InvivoGen (US)
Allergy Therapeutics (UK)
EuBiologics Co., Ltd. (South Korea)
Pacific GeneTech Limited (US)
Riboxx GmbH (Germany)
CaPtivate Pharmaceuticals LLC (US)
Creative Diagnostics (US)
LiteVax BV (Netherlands)
Mukta Industries (India)
Oncovir, Inc. (US)
TiterMax USA, Inc. (US).

Download Complete Report @ https://www.reportsnreports.com/purchase.aspx?name=597366

ReportsnReports - Your Market Research Librarian
Corporate Headquarters
Tower B5, office 101, Magarpatta SEZ,
Hadapsar, Pune-411013, India.
+ 1 347 333 3771
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.